DiaMedica Therapeutics Inc. (DMAC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

DiaMedica Therapeutics Inc. (DMAC) is down 29.0% since the beginning of the year. At $6 per share, DMAC is trading 45.8% below its 52-week high of $10. Investors who bought $1,000 worth of DMAC shares 5 years ago would now be looking at an investment worth $762.

DiaMedica Therapeutics Inc. (DMAC) has returned -29.02% so far this year and 37.14% over the past 12 months. Over the last ten years, DMAC has returned 5.21% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Jan 4, 2008, DMAC's average daily return is +0.13%, while the average monthly return is +2.11%. At this rate, an investment would double in approximately 2.8 years.

Historically, 41% of months were positive and 59% were negative. The best month was Nov 2009 with a return of +85.4%, while the worst month was Nov 2014 at -77.3%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, DMAC closed higher 25% of trading days. The best single day was Nov 11, 2014 with a return of +117.3%, while the worst single day was Nov 18, 2014 at -84.5%.

DiaMedica Therapeutics Inc. has an annualized alpha of 33.97%, beta of 0.37, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since January 07, 2008.

• This stock participated in 110.76% of S&P 500 Index downside but only 37.22% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.37 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

DMAC ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for DiaMedica Therapeutics Inc. (DMAC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the DiaMedica Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the DiaMedica Therapeutics Inc. was 98.16%, occurring on Dec 5, 2014. The portfolio has not yet recovered.

The current DiaMedica Therapeutics Inc. drawdown is 87.21%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of DiaMedica Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how DiaMedica Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.